Menu

Press Releases

Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment

, , ,

Undetectable Viral Load Sustained Over 20 Weeks in SB-728-902 Study; Data Demonstrate Dose Response in SB-728-1101 Cytoxan Study; Reduction of Viral Reservoir Observed in All Immune Non-Responders Over Three Years RICHMOND, Calif., Dec. 6, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of data from all dose cohorts in the Company’s ongoing clinical trials (SB-728-1101 […]

U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C

, , ,

– Sovaldi Approved for Use in Genotypes 1, 2, 3 or 4 – – High Cure Rates (SVR12) and Shortened, 12-Week Course of Therapy for Many Patients – – First Ever Oral Treatment Regimen for Genotypes 2 or 3 – – First Regimen for Patients Awaiting Liver Transplantation to Prevent HCV Recurrence – FOSTER CITY, […]

New Data Support Flexibility in Timing of Administration for Sanofi’s Lyxumia®

, , , ,

– Similar glucose lowering effect when once-daily Lyxumia is administered before breakfast or the main meal – PARIS, Dec. 5, 2013 /PRNewswire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the results of a 24-week Phase IIIb clinical study showing that Lyxumia® (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast […]

Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder

, , , ,

INDIANAPOLIS, Dec. 5, 2013 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor (SSRI), edivoxetine did not separate from placebo on the […]

Mylan Launches Cabergoline Tablets

, , ,

PITTSBURGH, Dec. 5, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration […]

Mylan Completes Acquisition of Agila to Create Leading Global Injectables Platform

, , ,

Purchase Price Restructured to Hold Back $250 Million Contingent Upon Satisfaction of Certain Regulatory Conditions Mylan Board of Directors Sets April 11, 2014 as Date for Annual Meeting of Shareholders PITTSBURGH, Dec. 4, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has completed the acquisition of the Agila injectables businesses from Strides […]

Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting

, , ,

– New, Interim Phase 3 Data Highlight Prolonged Half-Life of ELOCTATE™ and ALPROLIX™ in Young Children – – 10 Abstracts, Including Oral Presentation, Highlight Data from Hemophilia Research and Development Program – CAMBRIDGE, Mass.–(December 3, 2013)–Biogen Idec (NASDAQ: BIIB) will present new data from its hemophilia clinical development and research programs at the 55th Annual Meeting of the […]

Varian Medical Systems Exhibits New Lightweight Wireless Flat-Panel Digital X-ray Image Detector for Imaging Extremities and for Neonatal Procedures

, , , , ,

A broad range of components for dose-efficient imaging systems, image processing workstations, and cancer treatment technologies, are on display at RSNA in Chicago CHICAGO, Dec. 2, 2013 /PRNewswire/ — Booth 4304 — A new lightweight wireless flat-panel digital X-ray image detector ideal for imaging extremities and for use in neonatal imaging systems is among the imaging components that […]

Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation

, , , , ,

More than 10,000 people with self-reported and diagnosed type 2 diabetes and more than 6,500 treating-physicians from 26 countries to take part in new survey RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 2, 2013 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the launch of the largest multinational survey to investigate early […]

Forest to Acquire U.S. Marketing Rights to Saphris® (asenapine) from Merck

, , , ,

Forest acquires exclusive rights to Saphris® in the United States for the treatment of schizophrenia and acute bipolar mania in adults for $240 million plus sales-based milestones and on-going supply payments Saphris is complementary to Forest’s existing CNS franchise and commercial infrastructure Agreement is expected to be immediately accretive to Forest NEW YORK —  December […]

«‹ 94 95 96 97›»